Insulet Co. (NASDAQ:PODD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $243.21.

PODD has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Stifel Nicolaus raised their target price on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Robert W. Baird raised shares of Insulet from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $180.00 to $238.00 in a research note on Thursday, December 21st. Barclays dropped their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Finally, Piper Sandler decreased their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd.

Insulet Trading Down 3.7 %

Shares of Insulet stock opened at $166.26 on Friday. Insulet has a 12-month low of $125.82 and a 12-month high of $335.91. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. The stock has a market cap of $11.64 billion, a PE ratio of 57.13, a price-to-earnings-growth ratio of 3.13 and a beta of 0.98. The company has a 50-day moving average of $175.14 and a two-hundred day moving average of $178.90.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. On average, research analysts anticipate that Insulet will post 3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.80% of the stock is owned by insiders.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Manhattan Co. bought a new stake in shares of Insulet in the 4th quarter worth approximately $35,000. Wolff Wiese Magana LLC grew its position in Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. Benjamin F. Edwards & Company Inc. purchased a new position in Insulet during the fourth quarter valued at approximately $34,000. Sunbelt Securities Inc. purchased a new position in Insulet during the first quarter valued at approximately $29,000. Finally, Parkside Financial Bank & Trust grew its position in Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.